<strong>Background:</strong><span style="font-family:;" "=""><span style="font-family:Verdana;"> Gabapentin is routinely prescribed preoperatively to decrease...<strong>Background:</strong><span style="font-family:;" "=""><span style="font-family:Verdana;"> Gabapentin is routinely prescribed preoperatively to decrease postoperative pain intensity. It is included in the enhanced recovery after surgery (ERAS) recommendations. </span><b><span style="font-family:Verdana;">Objective:</span></b><span style="font-family:Verdana;"> To analyze correlation of gabapentin dosage and post anesthesia care unit (PACU) length of stay (LOS) and cost. </span><b><span style="font-family:Verdana;">Study Design:</span></b><span style="font-family:Verdana;"> A retrospective chart review of patients who underwent general anesthesia and received preoperative oral gabapentin from June 2017 </span></span><span style="font-family:Verdana;">to</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> August 2017 for pelvic and breast procedures. The main outcome was correlation between PACU LOS and gabapentin dosage in the outpatients. Financial analysis was performed to assess the cost to the hospital associated with increased LOS. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> Of the 636 patients, 405 patients received 300 </span><span style="font-family:Verdana;">mg and 231 patients received 100 mg gabapentin. Mean dosage per kg (mg/k</span><span style="font-family:Verdana;">g ±</span></span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">SD) was 3.12</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">±</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">1.51 (range: </span><span style="font-family:Verdana;">0</span><span style="font-family:Verdana;">.86 to 6.12). PACU LOS was 96</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">±</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">77 (minutes ±</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">SD) in patients receiving 100 mg and 120</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">±</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">96 in patients receiving 300 mg capsule (p</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">=</span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">0.001). Linear regression analysis, failed to show a </span><span style="font-family:Verdana;">statistically significant correlation between per kg dosage and PACU LOS (</span><span style="font-family:Verdana;">p</span></span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">=</span><span style="font-family:Verdana;"> 0</span><span style="font-family:Verdana;">.13). Using multiple regression analysis, we calculated the correlation coefficient to be +1.71 minutes per 1mg/kg gabapentin (95% CI: -</span><span style="font-family:Verdana;">3.75 to +7.10, p</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">=</span><span style="font-family:Verdana;"> 0</span><span style="font-family:Verdana;">.54) after adjusting for confounders. Adding 3</span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">mg/kg to pre-op g</span><span style="font-family:Verdana;">abapentin dosage of all outpatients cost on average</span></span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> an extra $9794 per mo</span><span style="font-family:;" "=""><span style="font-family:Verdana;">nth in this cohort. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> Every 1mg/kg increase in gabapentin dosage adds an estimated 7.1 minutes to PACU LOS. A 3</span></span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">mg/kg increase in gabapentin adds estimated 22 additional minutes in PACU LOS. Unfortunately, increase LOS is associated with increased hospital costs.</span>展开更多
目的研究麻醉复苏室(Post-anesthesia care unit,PACU)护士对麻醉苏醒期风险认知和患者安全胜任力现状,并分析麻醉苏醒期风险认知和患者安全胜任力相关性的影响因素。方法采用分层多阶段聚类抽样法于2022年6月-8月抽取新疆16所综合性医...目的研究麻醉复苏室(Post-anesthesia care unit,PACU)护士对麻醉苏醒期风险认知和患者安全胜任力现状,并分析麻醉苏醒期风险认知和患者安全胜任力相关性的影响因素。方法采用分层多阶段聚类抽样法于2022年6月-8月抽取新疆16所综合性医院的228名PACU护士为研究对象,采用电子问卷形式,问卷由一般资料、麻醉苏醒期风险认知调查问卷和患者安全胜任力护士评价量表组成,收集PACU护士对麻醉苏醒期风险认知和患者安全胜任力情况,分析患者安全胜任力和麻醉苏醒期风险认知的相关性及影响因素。结果PACU护士麻醉苏醒期风险认知总得分为(97.34±8.06)分,患者安全胜任力护士评价量表总得分为(148.72±11.80)分。在不同医院级别、学历、职称、麻醉护理工作年限、麻醉风险应急预案和麻醉风险培训频率PACU护士的患者安全胜任力和麻醉苏醒期风险认知差异均有统计学意义(P<0.05)。Pearson相关性分析显示,PACU护士麻醉苏醒期风险认知与患者安全胜任力各维度呈正相关(P<0.05)。多元线性回归分析显示,麻醉护理工作年限、职称、麻醉风险培训频率、苏醒期风险认知总分是PACU护士患者安全胜任力的影响因素(P均<0.05)。结论PACU护士的麻醉苏醒期风险认知和患者安全胜任力处于中等偏上水平,麻醉苏醒期风险认知水平的改善有助于PACU护士提高患者安全胜任力。展开更多
目的检测重症监护谵妄筛查量表(Intensive Care Delirium Screening Checklist,ICDSC)的信度和效度,为测评全麻术后麻醉苏醒期患者的谵妄状态提供有效工具。方法根据ISPOR指南,对国际通用的ICDSC进行编译,制定中文版ICDSC,对228例手术...目的检测重症监护谵妄筛查量表(Intensive Care Delirium Screening Checklist,ICDSC)的信度和效度,为测评全麻术后麻醉苏醒期患者的谵妄状态提供有效工具。方法根据ISPOR指南,对国际通用的ICDSC进行编译,制定中文版ICDSC,对228例手术后麻醉恢复室留观患者进行谵妄评估,对中文版ICDSC进行信度和效度分析。结果中文版ICDSC内部一致性Cronbach′sα系数为0.74,评分员间信度为0.90;以DSM-Ⅳ诊断结果为金标准,ICDSC诊断域值≥4分时,敏感度为0.97,特异度为0.83,阳性预测值为0.52,阴性预测值为0.99,ICDSC与DSM-Ⅳ总一致性的Kappa值为0.59(P<0.01)。ROC曲线下面积为0.93。结论中文版ICDSC具有满意的信度和效度,具有较高的诊断效能,可作为麻醉恢复室谵妄筛查工具,但诊断阳性者仍需专科医生进一步鉴别诊断排除其他疾病。展开更多
目的探讨麻醉恢复室(post-anesthesia care unit,PACU)入室护理流程的临床实践效果。方法建立PACU入室护理流程,内容包括连接呼吸机、连接监护仪、管道交接、皮肤交接等流程和对PACU护士进行培训、考核。结果流程应用前,术后患者入室护...目的探讨麻醉恢复室(post-anesthesia care unit,PACU)入室护理流程的临床实践效果。方法建立PACU入室护理流程,内容包括连接呼吸机、连接监护仪、管道交接、皮肤交接等流程和对PACU护士进行培训、考核。结果流程应用前,术后患者入室护理时间从7.0 min降至流程应用后4.0 min,无1例发生护理风险及不良事件。结论 PACU入室护理流程的应用提高了护理质量,加强了患者安全。展开更多
文摘<strong>Background:</strong><span style="font-family:;" "=""><span style="font-family:Verdana;"> Gabapentin is routinely prescribed preoperatively to decrease postoperative pain intensity. It is included in the enhanced recovery after surgery (ERAS) recommendations. </span><b><span style="font-family:Verdana;">Objective:</span></b><span style="font-family:Verdana;"> To analyze correlation of gabapentin dosage and post anesthesia care unit (PACU) length of stay (LOS) and cost. </span><b><span style="font-family:Verdana;">Study Design:</span></b><span style="font-family:Verdana;"> A retrospective chart review of patients who underwent general anesthesia and received preoperative oral gabapentin from June 2017 </span></span><span style="font-family:Verdana;">to</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> August 2017 for pelvic and breast procedures. The main outcome was correlation between PACU LOS and gabapentin dosage in the outpatients. Financial analysis was performed to assess the cost to the hospital associated with increased LOS. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> Of the 636 patients, 405 patients received 300 </span><span style="font-family:Verdana;">mg and 231 patients received 100 mg gabapentin. Mean dosage per kg (mg/k</span><span style="font-family:Verdana;">g ±</span></span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">SD) was 3.12</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">±</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">1.51 (range: </span><span style="font-family:Verdana;">0</span><span style="font-family:Verdana;">.86 to 6.12). PACU LOS was 96</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">±</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">77 (minutes ±</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">SD) in patients receiving 100 mg and 120</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">±</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">96 in patients receiving 300 mg capsule (p</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">=</span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">0.001). Linear regression analysis, failed to show a </span><span style="font-family:Verdana;">statistically significant correlation between per kg dosage and PACU LOS (</span><span style="font-family:Verdana;">p</span></span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">=</span><span style="font-family:Verdana;"> 0</span><span style="font-family:Verdana;">.13). Using multiple regression analysis, we calculated the correlation coefficient to be +1.71 minutes per 1mg/kg gabapentin (95% CI: -</span><span style="font-family:Verdana;">3.75 to +7.10, p</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">=</span><span style="font-family:Verdana;"> 0</span><span style="font-family:Verdana;">.54) after adjusting for confounders. Adding 3</span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">mg/kg to pre-op g</span><span style="font-family:Verdana;">abapentin dosage of all outpatients cost on average</span></span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> an extra $9794 per mo</span><span style="font-family:;" "=""><span style="font-family:Verdana;">nth in this cohort. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> Every 1mg/kg increase in gabapentin dosage adds an estimated 7.1 minutes to PACU LOS. A 3</span></span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">mg/kg increase in gabapentin adds estimated 22 additional minutes in PACU LOS. Unfortunately, increase LOS is associated with increased hospital costs.</span>
文摘目的研究麻醉复苏室(Post-anesthesia care unit,PACU)护士对麻醉苏醒期风险认知和患者安全胜任力现状,并分析麻醉苏醒期风险认知和患者安全胜任力相关性的影响因素。方法采用分层多阶段聚类抽样法于2022年6月-8月抽取新疆16所综合性医院的228名PACU护士为研究对象,采用电子问卷形式,问卷由一般资料、麻醉苏醒期风险认知调查问卷和患者安全胜任力护士评价量表组成,收集PACU护士对麻醉苏醒期风险认知和患者安全胜任力情况,分析患者安全胜任力和麻醉苏醒期风险认知的相关性及影响因素。结果PACU护士麻醉苏醒期风险认知总得分为(97.34±8.06)分,患者安全胜任力护士评价量表总得分为(148.72±11.80)分。在不同医院级别、学历、职称、麻醉护理工作年限、麻醉风险应急预案和麻醉风险培训频率PACU护士的患者安全胜任力和麻醉苏醒期风险认知差异均有统计学意义(P<0.05)。Pearson相关性分析显示,PACU护士麻醉苏醒期风险认知与患者安全胜任力各维度呈正相关(P<0.05)。多元线性回归分析显示,麻醉护理工作年限、职称、麻醉风险培训频率、苏醒期风险认知总分是PACU护士患者安全胜任力的影响因素(P均<0.05)。结论PACU护士的麻醉苏醒期风险认知和患者安全胜任力处于中等偏上水平,麻醉苏醒期风险认知水平的改善有助于PACU护士提高患者安全胜任力。
文摘目的检测重症监护谵妄筛查量表(Intensive Care Delirium Screening Checklist,ICDSC)的信度和效度,为测评全麻术后麻醉苏醒期患者的谵妄状态提供有效工具。方法根据ISPOR指南,对国际通用的ICDSC进行编译,制定中文版ICDSC,对228例手术后麻醉恢复室留观患者进行谵妄评估,对中文版ICDSC进行信度和效度分析。结果中文版ICDSC内部一致性Cronbach′sα系数为0.74,评分员间信度为0.90;以DSM-Ⅳ诊断结果为金标准,ICDSC诊断域值≥4分时,敏感度为0.97,特异度为0.83,阳性预测值为0.52,阴性预测值为0.99,ICDSC与DSM-Ⅳ总一致性的Kappa值为0.59(P<0.01)。ROC曲线下面积为0.93。结论中文版ICDSC具有满意的信度和效度,具有较高的诊断效能,可作为麻醉恢复室谵妄筛查工具,但诊断阳性者仍需专科医生进一步鉴别诊断排除其他疾病。
文摘目的探讨参考《患者离室标准》制定的《转运前护理观察指标》应用于全麻手术患者的效果。方法便利抽样选择2013年5-8月南方医院300例成年择期行全身麻醉的手术患者,按手术时间分成两组,对照组(control group)患者由麻醉恢复室(post-anesthesia care unit,PACU)医生在患者离室标准的基础上,根据个人经验观察后,进行Steward评分,之后通知护士转运;观察组(observation group)患者由PACU护士按照《转运前护理观察指标》的要求进行判断,满足条件后通知PACU医生进行Steward评分,之后遵医嘱转送。比较两组患者满足转送条件时间、实际转送时间、转送至病房后术后基本情况的差异。结果观察组患者PACU的满足转运条件时间和实际转运时间均明显短于对照组(均P<0.05);两组患者转送至病房后不良事件发生率差异无统计学意义(均P>0.05)。结论麻醉护士执行预先制定的《转运前护理观察指标》,主动进行患者转运前病情观察,可明显缩短患者留置PACU时间,提高医疗和护理工作效率。